Avian ("Bird") Flu Stocks Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avian ("Bird") Flu Stocks

NNVC 1.850

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: manny t	10/27/2005 9:03:26 AM
	of 428

SVA news, BEIJING--(BUSINESS WIRE)--Oct. 27, 2005--Sinovac Biotech Ltd. (AMEX:SVA - News), a leading Chinese biotechnology company in vaccine development and marketing, has announced that the State Food and Drug Administration (SFDA) issued a GMP (Good Manufacturing Practices) certificate for Sinovac's proprietary influenza flu vaccine, Anflu(TM). The GMP certificate is the final approval required to sell Anflu(TM) vaccine in China (PRC). ADVERTISEMENT Sinovac Director and CEO Mr. Weidong Yin commented "Sinovac continues to implement its business strategy at an ever increasing tempo. Anflu(TM) is the third product our Company has taken from R&D to sales, and we have avian flu and Japanese Encephalitis vaccines in the pipeline." Anflu(TM) is a modern split flu type vaccine, which typically does not produce side effects. Therefore, Anflu(TM) is much better suited to inoculating children and seniors (the two groups most at risk from influenza). Anflu(TM) is produced in a new manufacturing facility with a full production capacity of 2 million doses of flu vaccine per year. The Company plans to build a much larger manufacturing facility of this type once it obtains financing. Since the majority of vaccinations in China occur in September and October, Management expects Anflu(TM) will become a driver for sales in 2006. Sinovac's successful development of a seasonal influenza vaccine is a key element in technological transfer to the research and development of pandemic influenza vaccine (H5N1). Currently, this vaccine development is in preclinical stage. Receiving GMP certification for Anflu(TM) will act as a catalyst for Sinovac's pandemic influenza vaccine (H5N1) development.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next